Trial Profile
Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Combination Therapy for Pulmonary Tuberculosis (TB): a Randomized, Double-blind, Placebo-controlled, Proof-of-concept Clinical Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2023
Price :
$35
*
At a glance
- Drugs Pascolizumab (Primary)
- Indications Pulmonary tuberculosis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 17 Aug 2017 New trial record